← Oncology Approval Tracker

FDA DECISION ·

Rybrevant + carboplatin + pemetrexed

amivantamab-vmjw with carboplatin and pemetrexed · Janssen Biotech

FDA approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with locally advanced or metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation and progression on or after an EGFR tyrosine kinase inhibitor.

LAMPGEN ANALYSIS

Why it matters

This combination adds an antibody-based option after EGFR inhibitor failure for common EGFR variants.

What research teams should watch

Distinguish the EGFR variant and progression setting from the exon 20 insertion regimen; reserve adequate infusion and observation capacity.

PRIMARY RECORDS

Sources